V&M Industries will underwrite sales and marketing costs related to the Microcyn-based over-the-counter (OTC) skin and wound care formulations.
Hoji Alimi, founder and CEO of Oculus, said: "The management team at V&M has proven its ability to champion a wide variety of products from concept to profitability in relatively short order. They have built a seasoned marketing team that understands the dynamics of the US over-the-counter space and are prepared to fully invest so as to generate meaningful sales for the Microcyn OTC products.
"This further validates the wisdom of the Oculus business model in which we license key product niches to strong partners who underwrite the costs of product marketing while we share in the revenues. This allows us to maintain our reduced overhead with a focus on our target of cash breakeven by March of 2010."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index